期刊
JOURNAL OF INFECTIOUS DISEASES
卷 197, 期 4, 页码 580-583出版社
UNIV CHICAGO PRESS
DOI: 10.1086/526537
关键词
-
资金
- NCRR NIH HHS [M01 RR00044, RR165001, M01-RR00425] Funding Source: Medline
- NIAID NIH HHS [AI 30068, AI 25461, AI 25463, N01 AI 25460] Funding Source: Medline
Previously, we evaluated 2 doses of H5N1 influenza vaccine in persons 18-64 years of age (placebo and 7.5-, 15-, 45-, or 90-mu g doses), separated by 28 days. In this study, 337 participants received a third dose, 6 months thereafter. Microneutralization (MN) and hemagglutination-inhibition geometric mean titers(GMTs) of antibody declined before the third dose. Twenty-eight days after the third dose, 78%, 67%, 43%, and 31% of recipients in the 90-, 45-, 15-, and 7.5-mu g-dose groups had a MN GMT >= 1:40, respectively. Five months later, MN GMTs were significantly greater than those after the second dose. (Trial registration: Clinical Trials.gov identifier NCT00240968.).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据